OBIO — Orchestra Biomed Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $166.01m
- $78.41m
- $2.76m
Annual cashflow statement for Orchestra Biomed Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 8-K | 8-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -21.4 | -23 | -33.6 | -49.1 |
| Depreciation | ||||
| Non-Cash Items | 3.22 | 0.774 | 4.55 | 6.01 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -8.19 | 2.63 | -0.451 | -3.31 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -26.2 | -19.4 | -29.3 | -46.1 |
| Capital Expenditures | -0.539 | -0.274 | -0.591 | -0.078 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 27.5 | 13.3 | -63.5 | 10.8 |
| Sale/Maturity of Investment | ||||
| Change in Net Investments | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | 27 | 13 | -64.1 | 10.7 |
| Financing Cash Flow Items | — | 0 | -10.3 | 56.8 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 10 | -3.99 | 103 | 46.2 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 10.8 | -10.4 | 9.85 | 10.8 |